Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine   Commentary on Twitter ?Just OutACTT-4 Trial?First Double Placebo-Controlled Double-Blind Randomized-Stratified Head-to-Head#DEXAMETHASONE vs #BARICITINIB for hospitalized pts w/#COVID19 Low/High-Flow/NIVRelevant?Patient Care/Public Health/GuidelinesOur results?https://t.co/4Tmue7HK7V ?1/4 pic.twitter.com/aF1Y7BAdu3 — Andre Kalil, MD MPH (@DrAndreKalil) May 24, 2022  

The post RCT: Baricitinib vs. dexamethasone for adults hospitalized with COVID-19. appeared first on Links Medicus.